{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T21:25:41Z","timestamp":1783286741460,"version":"3.54.6"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K07597"],"award-info":[{"award-number":["20K07597"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K10508"],"award-info":[{"award-number":["20K10508"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K09873"],"award-info":[{"award-number":["19K09873"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K06969"],"award-info":[{"award-number":["22K06969"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K06432"],"award-info":[{"award-number":["23K06432"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K09616"],"award-info":[{"award-number":["21K09616"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-70779-8","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T03:21:30Z","timestamp":1724728890000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["PD-L1 expression as a predictive biomarker in patients with recurrent or metastatic salivary gland carcinoma treated with pembrolizumab"],"prefix":"10.1038","volume":"14","author":[{"given":"Takashi","family":"Matsuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Kawakita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuro","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushi","family":"Ueki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tsuge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Hanyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaho","family":"Momiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusuke","family":"Shodo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayu","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Asako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshitaka","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Tada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,27]]},"reference":[{"key":"70779_CR1","doi-asserted-by":"publisher","first-page":"209249","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J. Clin. 71, 209249 (2021).","journal-title":"Cancer J. Clin."},{"key":"70779_CR2","unstructured":"El-Naggar, A., Chan, J. K. C. & Grandis, J. WHO classification of head neck tumours, 4th edition, volume 9; 7 tumours of salivary glands. World Health Organization 2017: pp 159. (2017)."},{"key":"70779_CR3","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1200\/JCO.21.00449","volume":"39","author":"JL Geiger","year":"2021","unstructured":"Geiger, J. L. et al. Management of salivary gland malignancy: ASCO guideline. J. Clin. Oncol. Official J Am. Soc. Clin. Oncol. 39, 1909\u20131941 (2021).","journal-title":"J. Clin. Oncol. Official J Am. Soc. Clin. Oncol."},{"key":"70779_CR4","doi-asserted-by":"publisher","first-page":"100602","DOI":"10.1016\/j.esmoop.2022.100602","volume":"7","author":"C van Herpen","year":"2022","unstructured":"van Herpen, C. et al. Salivary gland cancer: ESMO-European reference network on rare adult solid cancers (EURACAN) clinical practice guideline for diagnosis, treatment and follow-up. ESMO Open. 7, 100602 (2022).","journal-title":"ESMO Open."},{"key":"70779_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1200\/JCO.18.00545","volume":"37","author":"H Takahashi","year":"2019","unstructured":"Takahashi, H. et al. Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma. J. Clin. Oncol. Official J. Am. Soc. Clin. Oncol. 37, 125\u2013134 (2019).","journal-title":"J. Clin. Oncol. Official J. Am. Soc. Clin. Oncol."},{"key":"70779_CR6","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/annonc\/mdx771","volume":"29","author":"C Fushimi","year":"2018","unstructured":"Fushimi, C. et al. A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. Ann. Oncol. Official J. Eur. Soc. Med. Oncol. 29, 979\u2013984 (2018).","journal-title":"Ann. Oncol. Official J. Eur. Soc. Med. Oncol."},{"key":"70779_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac080","author":"X Le","year":"2022","unstructured":"Le, X. et al. Larotrectinib treatment for patients with TRK fusion-positive salivary gland cancers. Oncol. https:\/\/doi.org\/10.1093\/oncolo\/oyac080 (2022).","journal-title":"Oncol."},{"key":"70779_CR8","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle, A. et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 21, 1353\u20131365 (2020).","journal-title":"Lancet Oncol."},{"key":"70779_CR9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ejca.2022.05.007","volume":"171","author":"C Even","year":"2022","unstructured":"Even, C. et al. Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study. Eur. J.Cancer 171, 259\u2013268 (2022).","journal-title":"Eur. J.Cancer"},{"key":"70779_CR10","doi-asserted-by":"publisher","first-page":"6092","DOI":"10.1200\/JCO.2023.41.16_suppl.6092","volume":"41","author":"Y Nagatani","year":"2023","unstructured":"Nagatani, Y. et al. A phase II trial of nivolumab for patients with platinum-refractory recurrent or metastatic salivary gland cancer. J. Clin. Oncol. Official J. Am. Soc. Clin. Oncol. 41, 6092 (2023).","journal-title":"J. Clin. Oncol. Official J. Am. Soc. Clin. Oncol."},{"key":"70779_CR11","doi-asserted-by":"publisher","first-page":"16988","DOI":"10.1038\/s41598-020-73965-6","volume":"10","author":"K Niwa","year":"2020","unstructured":"Niwa, K. et al. Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma. Sci Rep. 10, 16988 (2020).","journal-title":"Sci Rep."},{"key":"70779_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2023-000065","author":"J Fayette","year":"2023","unstructured":"Fayette, J., Even, C., Digue, L., Geoffrois, L. & Rolland, F. NISCAHN: A phase II trial of nivolumab in patients with salivary gland carcinoma (Unicancer ORL-08). BMJ Oncol. https:\/\/doi.org\/10.1136\/bmjonc-2023-000065 (2023).","journal-title":"BMJ Oncol."},{"key":"70779_CR13","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1097\/COC.0000000000000429","volume":"41","author":"RB Cohen","year":"2018","unstructured":"Cohen, R. B. et al. Pembrolizumab for the treatment of advanced salivary gland carcinoma: findings of the phase 1b KEYNOTE-028 study. Am. J. Clin. Oncol. 41, 1083\u20131088 (2018).","journal-title":"Am. J. Clin. Oncol."},{"key":"70779_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02518-x","author":"JL Vos","year":"2023","unstructured":"Vos, J. L. et al. Nivolumab plus ipilimumab in advanced salivary gland cancer: A phase 2 trial. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-023-02518-x (2023).","journal-title":"Nat. Med."},{"key":"70779_CR15","unstructured":". NCCN Clinical Practice Guidelines in Oncology, Head and Neck Cancers Version 2.2024 https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/head-and-neck.pdf. Accessed February, 29 2024."},{"key":"70779_CR16","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness, B. et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study. Lancet (London, England). 394, 1915\u20131928 (2019).","journal-title":"Lancet (London, England)."},{"key":"70779_CR17","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes, J. et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N. Engl. J. Med. 387, 217\u2013226 (2022).","journal-title":"N. Engl. J. Med."},{"key":"70779_CR18","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1093\/annonc\/mdx008","volume":"28","author":"R Hui","year":"2017","unstructured":"Hui, R. et al. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: A phase 1 trial. Ann. Oncol. Official J. Eur. Soc. Med. Oncol. 28, 874\u2013881 (2017).","journal-title":"Ann. Oncol. Official J. Eur. Soc. Med. Oncol."},{"key":"70779_CR19","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1158\/1078-0432.CCR-19-3758","volume":"26","author":"M Linxweiler","year":"2020","unstructured":"Linxweiler, M. et al. The immune microenvironment and neoantigen landscape of aggressive salivary gland carcinomas differ by subtype. Clin. Cancer Res. Official J. Am. Assoc. Cancer Res. 26, 2859\u20132870 (2020).","journal-title":"Clin. Cancer Res. Official J. Am. Assoc. Cancer Res."},{"key":"70779_CR20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/jso.24266","volume":"114","author":"T Mukaigawa","year":"2016","unstructured":"Mukaigawa, T. et al. Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas. J. Surg. Oncol. 114, 36\u201343 (2016).","journal-title":"J. Surg. Oncol."},{"key":"70779_CR21","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00428-023-03598-3","volume":"483","author":"H Hirai","year":"2023","unstructured":"Hirai, H. et al. Prognostic value and clinicopathological roles of the tumor immune microenvironment in salivary duct carcinoma. Virchows Arch. 483, 367\u2013379 (2023).","journal-title":"Virchows Arch."},{"key":"70779_CR22","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3892\/ol.2023.14024","volume":"26","author":"C Liu","year":"2023","unstructured":"Liu, C. et al. Prognostic value of nutritional and inflammatory markers in patients with hepatocellular carcinoma who receive immune checkpoint inhibitors. Oncol. Lett. 26, 437 (2023).","journal-title":"Oncol. Lett."},{"key":"70779_CR23","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/lio2.1070","volume":"8","author":"T Oka","year":"2023","unstructured":"Oka, T. et al. Prognostic values of systemic inflammation and nutrition-based prognostic indices in oropharyngeal carcinoma. Laryngoscope Investing. Oto. 8, 675\u2013685 (2023).","journal-title":"Laryngoscope Investing. Oto."},{"key":"70779_CR24","doi-asserted-by":"publisher","first-page":"e048324","DOI":"10.1136\/bmjopen-2020-048324","volume":"11","author":"Y Jiang","year":"2021","unstructured":"Jiang, Y. et al. Inflammation and nutrition-based biomarkers in the prognosis of oesophageal cancer: A systematic review and meta-analysis. BMJ Open 11, e048324 (2021).","journal-title":"BMJ Open"},{"key":"70779_CR25","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00423-023-02786-8","volume":"408","author":"G Portale","year":"2023","unstructured":"Portale, G., Bartolotta, P., Azzolina, D., Gregori, D. & Fiscon, V. Prognostic role of platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte, and lymphocyte-to-monocyte ratio in operated rectal cancer patients: Systematic review and meta-analysis. Langenbeck Arch. Surg. 408, 85 (2023).","journal-title":"Langenbeck Arch. Surg."},{"key":"70779_CR26","doi-asserted-by":"publisher","first-page":"5015","DOI":"10.1002\/cam4.3124","volume":"9","author":"T Matsuki","year":"2020","unstructured":"Matsuki, T. et al. Hematological predictive markers for recurrent or metastatic squamous cell carcinomas of the head and neck treated with nivolumab: A multicenter study of 88 patients. Cancer Medi. 9, 5015\u20135024 (2020).","journal-title":"Cancer Medi."},{"key":"70779_CR27","doi-asserted-by":"publisher","first-page":"100445","DOI":"10.1016\/j.esmoop.2022.100445","volume":"7","author":"M Stares","year":"2022","unstructured":"Stares, M. et al. Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer. ESMO Open 7, 100445 (2022).","journal-title":"ESMO Open"},{"key":"70779_CR28","doi-asserted-by":"publisher","first-page":"1003581","DOI":"10.3389\/fimmu.2022.1003581","volume":"13","author":"X Zhao","year":"2022","unstructured":"Zhao, X. et al. Prognostic value of hematologic parameters in advanced non-small cell lung cancer patients receiving anti-PD-1 inhibitors. Front. immunol. 13, 1003581 (2022).","journal-title":"Front. immunol."},{"key":"70779_CR29","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.21873\/anticanres.14921","volume":"41","author":"Y Kadono","year":"2021","unstructured":"Kadono, Y. et al. Blood cell count biomarkers predicting efficacy of pembrolizumab as second-line therapy for advanced urothelial carcinoma. Anticancer Res. 41, 1599\u20131606 (2021).","journal-title":"Anticancer Res."},{"key":"70779_CR30","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.21873\/anticanres.15781","volume":"42","author":"E Booka","year":"2022","unstructured":"Booka, E. et al. Neutrophil-to-lymphocyte ratio to predict the efficacy of immune checkpoint inhibitor in upper gastrointestinal cancer. Anticancer Res. 42, 2977\u20132987 (2022).","journal-title":"Anticancer Res."},{"key":"70779_CR31","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nrc3004","volume":"11","author":"LJ Gay","year":"2011","unstructured":"Gay, L. J. & Felding-Habermann, B. Contribution of platelets to tumour metastasis. Nat. Rev. Cancer. 11, 123\u2013134 (2011).","journal-title":"Nat. Rev. Cancer."},{"key":"70779_CR32","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/JCO.21.02508","volume":"41","author":"KJ Harrington","year":"2023","unstructured":"Harrington, K. J. et al. Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: Updated results of the phase III KEYNOTE-048 study. J. Clin. Oncol. Official J. Am. Soc. Clin. Oncol. 41, 790\u2013802 (2023).","journal-title":"J. Clin. Oncol. Official J. Am. Soc. Clin. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-70779-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-70779-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-70779-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T13:09:24Z","timestamp":1725023364000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-70779-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,27]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["70779"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-70779-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,27]]},"assertion":[{"value":"18 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19794"}}